{"id":"400mg","_fda":{"id":"6225e033-9578-451d-ba0b-16e2a5e0322c","set_id":"2ea68874-8c20-4284-bd0a-f07768057b83","openfda":{"upc":["0369168174061"],"unii":["3A3U0GI71G"],"route":["ORAL"],"rxcui":["198741"],"spl_id":["6225e033-9578-451d-ba0b-16e2a5e0322c"],"brand_name":["Magnesium Oxide 400mg"],"spl_set_id":["2ea68874-8c20-4284-bd0a-f07768057b83"],"package_ndc":["69168-174-06"],"product_ndc":["69168-174"],"generic_name":["MAGNESIUM OXIDE 400MG"],"product_type":["HUMAN OTC DRUG"],"substance_name":["MAGNESIUM OXIDE"],"manufacturer_name":["Allegiant Health"],"application_number":["M001"],"is_original_packager":[true]},"purpose":["Purpose Antacid"],"version":"2","warnings":["WARNINGS Ask a doctor if you have kidney disease Ask a doctor or pharmacist before use if you are taking a prescription drug. Antacids may interact with certain prescription drugs. Do not take more than 2 tablets in a 24 hour period or use the maximum dosage of this product for more than two weeks, except under the advise and supervision of a physician If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. Keep out of reach of children."],"ask_doctor":["Ask a doctor if you have kidney disease"],"effective_time":"20190128","active_ingredient":["ACTIVE INGREDIENT (In each tablet) Magnesium Oxide 400mg (241.3mg elemental magnesium) Purpose Antacid"],"inactive_ingredient":["INACTIVE INGREDIENTS colloidal silicon dioxide, croscarmellose sodium, microcrystalline cellulose, stearic acid"],"indications_and_usage":["USES relieves acid indigestion upset stomach"],"ask_doctor_or_pharmacist":["Ask a doctor or pharmacist before use if you are taking a prescription drug. Antacids may interact with certain prescription drugs."],"spl_unclassified_section":["OTHER INFORMATION Magnesium content per tablet: 241.3mg store at room temperature 59°-86° F (15°-30°C) do not use if imprinted safety seal under cap is broken or missing"],"dosage_and_administration":["DIRECTIONS Antacid Directions: take 1 tablet twice a day or as directed by a physician Magnesium Supplement Directions: take 1 to 2 tablets daily or as directed by a physician"],"spl_product_data_elements":["Magnesium Oxide 400mg Magnesium Oxide 400mg MAGNESIUM OXIDE MAGNESIUM CATION SILICON DIOXIDE CROSCARMELLOSE SODIUM CELLULOSE, MICROCRYSTALLINE STEARIC ACID 174"],"pregnancy_or_breast_feeding":["If pregnant or breast-feeding, ask a health professional before use."],"keep_out_of_reach_of_children":["Keep out of reach of children. Keep out of reach of children."],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL Magnesium Oxide 400mg Magnesium Oxide 400mg"]},"safety":{"boxedWarnings":[]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=400mg","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T04:28:48.512920+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T04:29:13.122839+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T04:28:53.808295+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=400mg","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T04:28:54.095303+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T04:28:47.384964+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T04:29:02.609907+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T04:28:47.384996+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"M001","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T04:28:47.385000+00:00"}},"_dailymed":{"setId":"6c4bc7d1-09d9-4311-8457-a1d47ab02a5a","title":"MUCUS RELIEF DM (DEXTROMETHORPHAN HBR 20MG GUAIFENESIN 400MG) TABLET [NUVICARE LLC]"},"aiSummary":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.'s 400mg drug, currently marketed for acid indigestion relief, holds a position in a competitive therapeutic area. The key composition patent, set to expire in 2028, provides a significant period of market exclusivity, enhancing the drug's competitive edge. The primary risk lies in the potential increase in competition post-patent expiry, which could impact market share and revenue.","_scrapedAt":"2026-03-28T06:53:29.137Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T04:29:13.122917+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"id":"400mg-acid-indigestion-relief","name":"Acid Indigestion Relief","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Not specified","pivotalTrial":null,"restrictions":[],"patientPopulation":"Not specified","diagnosticRequired":null,"brandNameForIndication":""},{"id":"400mg-upset-stomach-relief","name":"Upset Stomach Relief","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Not specified","pivotalTrial":null,"restrictions":[],"patientPopulation":"Not specified","diagnosticRequired":null,"brandNameForIndication":""}]},"trialDetails":[{"nctId":"NCT07135232","phase":"NA","title":"The Effects of Resistance Training and a Plant-Based Supplement on Perimenopausal Symptoms and Muscle Health.","status":"RECRUITING","sponsor":"Leeds Beckett University","startDate":"2026-03-01","conditions":"Perimenopause, Menopause","enrollment":72},{"nctId":"NCT03485417","phase":"PHASE2, PHASE3","title":"Substance Misuse To Psychosis for Stimulants","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2019-06-01","conditions":"Stimulant Use With Stimulant-Induced Psychotic Disorder (Diagnosis), Schizophrenia and Related Disorders, Stimulant Dependence","enrollment":165},{"nctId":"NCT03605550","phase":"PHASE1","title":"A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2018-08-01","conditions":"High Grade Glioma, Diffuse Intrinsic Pontine Glioma","enrollment":64},{"nctId":"NCT03824483","phase":"PHASE2","title":"Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-02-22","conditions":"Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL)","enrollment":230},{"nctId":"NCT05853575","phase":"PHASE2","title":"Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mirati Therapeutics Inc.","startDate":"2024-02-16","conditions":"Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung","enrollment":200},{"nctId":"NCT04849728","phase":"PHASE3","title":"A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )","status":"ACTIVE_NOT_RECRUITING","sponsor":"Inventiva Pharma","startDate":"2021-08-19","conditions":"NASH - Nonalcoholic Steatohepatitis","enrollment":1000},{"nctId":"NCT00001309","phase":"PHASE1","title":"The Body's Affect on Vitamin C","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"1997-01-23","conditions":"Healthy Volunteers","enrollment":23},{"nctId":"NCT06406465","phase":"PHASE2","title":"A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Carcinoma, Neuroendocrine, Tumor, Neuroendocrine, Tumors, Neuroendocrine","enrollment":60},{"nctId":"NCT06312137","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-03","conditions":"Non Small Cell Lung Cancer","enrollment":780},{"nctId":"NCT06418724","phase":"PHASE2","title":"Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Melanoma and Skin Cancer Trials Limited","startDate":"2026-07-30","conditions":"Locally Advanced Cutaneous Squamous Cell Carcinoma","enrollment":27},{"nctId":"NCT07064005","phase":"PHASE1","title":"Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.","status":"ENROLLING_BY_INVITATION","sponsor":"Pravat Mandal","startDate":"2026-03-20","conditions":"Parkinsons Disease (PD)","enrollment":12},{"nctId":"NCT05112991","phase":"PHASE2","title":"Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer","status":"RECRUITING","sponsor":"3D Medicines (Sichuan) Co., Ltd.","startDate":"2022-03-04","conditions":"Advanced Endometrial Cancer","enrollment":108},{"nctId":"NCT07407140","phase":"PHASE3","title":"VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-30","conditions":"AML, Adult","enrollment":300},{"nctId":"NCT07493161","phase":"NA","title":"Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-01","conditions":"Ph+ ALL","enrollment":100},{"nctId":"NCT06561711","phase":"PHASE4","title":"Optimization of Minocycline for Helicobacter Pylori Rescue Treatment","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2024-08-21","conditions":"Helicobacter Pylori Infection","enrollment":480},{"nctId":"NCT02586857","phase":"PHASE1, PHASE2","title":"A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2016-01-25","conditions":"Glioblastoma Multiforme","enrollment":24},{"nctId":"NCT05128825","phase":"PHASE2","title":"A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer","status":"RECRUITING","sponsor":"K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc","startDate":"2022-02-17","conditions":"High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer","enrollment":170},{"nctId":"NCT05467891","phase":"PHASE2","title":"Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"Oana Danciu","startDate":"2022-09-13","conditions":"Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":200},{"nctId":"NCT03534323","phase":"PHASE1, PHASE2","title":"Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-07-12","conditions":"Chronic Lymphocytic Leukemia, Richter Syndrome","enrollment":55},{"nctId":"NCT05434104","phase":"NA","title":"The LISA (Lactoferrin InStead of Antibiotics/Antifungals) Feasibility Study","status":"NOT_YET_RECRUITING","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2026-03","conditions":"Bacterial Vaginosis, Candida Vaginal","enrollment":114},{"nctId":"NCT05911295","phase":"PHASE3","title":"Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2023-09-22","conditions":"Urothelial Carcinoma","enrollment":412},{"nctId":"NCT06493019","phase":"PHASE2","title":"Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer","status":"RECRUITING","sponsor":"Dustin Deming","startDate":"2024-09-30","conditions":"Anal Cancer","enrollment":23},{"nctId":"NCT06831955","phase":"PHASE2","title":"LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2026-02-01","conditions":"Triple Negative Breast Cancer (TNBC), Early Setting","enrollment":356},{"nctId":"NCT02215720","phase":"PHASE1","title":"Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2011-04-26","conditions":"Patients With Advanced or Metastatic Solid Tumors","enrollment":45},{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":"Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections","enrollment":300},{"nctId":"NCT07486726","phase":"PHASE1, PHASE2","title":"Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2026-03-15","conditions":"Acute Myeloid Leukemia (AML), Relapse Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia (AML)","enrollment":112},{"nctId":"NCT07136922","phase":"PHASE1","title":"First in Human Safety and Ease of Use Assessment of 400mg Progesterone Callavid in Women With Luteal Phase Insufficiency","status":"NOT_YET_RECRUITING","sponsor":"Calla Lily Clinical Care Ltd","startDate":"2026-04","conditions":"Luteal Phase Insuffiency, Progesterone Delivery","enrollment":20},{"nctId":"NCT03822780","phase":"NA","title":"Hydroxychloroquin (HCQ) in chILD of Genetic Defect","status":"COMPLETED","sponsor":"Children's Hospital of Fudan University","startDate":"2017-07-01","conditions":"Surfactant Dysfunction","enrollment":25},{"nctId":"NCT06220162","phase":"PHASE2","title":"VAC Regimen for AML Patients Who Failed to Response to VA Regimen","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-02-01","conditions":"Acute Myeloid Leukemia","enrollment":32},{"nctId":"NCT04720716","phase":"PHASE3","title":"A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2021-02-07","conditions":"Hepatocellular Carcinoma","enrollment":344},{"nctId":"NCT07153003","phase":"PHASE4","title":"Efficacy And Safety Of Tramadol And Oxycodone Versus Oxycodone Monotherapy For Pain Control After Primary Total Knee And Total Hip Arthroplasty","status":"ENROLLING_BY_INVITATION","sponsor":"Mayo Clinic","startDate":"2026-02-02","conditions":"Post Operative Pain","enrollment":560},{"nctId":"NCT05636514","phase":"PHASE1","title":"Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS","status":"RECRUITING","sponsor":"Clinical Hub for Interventional Research (CHOIR)","startDate":"2022-12-14","conditions":"Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia","enrollment":12},{"nctId":"NCT05478512","phase":"PHASE2","title":"Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2023-07-21","conditions":"High Risk CLL, Chronic Lymphocytic Leukemia","enrollment":78},{"nctId":"NCT06075953","phase":"PHASE2","title":"DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2024-02-17","conditions":"Ductal Carcinoma in Situ","enrollment":400},{"nctId":"NCT04246437","phase":"PHASE1","title":"[18F]F-DOPA Imaging in Patients With Autonomic Failure","status":"RECRUITING","sponsor":"Daniel Claassen","startDate":"2020-02-04","conditions":"Autonomic Failure, Pure Autonomic Failure, Parkinson Disease","enrollment":40},{"nctId":"NCT05524077","phase":"NA","title":"Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Western Sydney Local Health District","startDate":"2020-07-08","conditions":"Heart Disease Structural Disorder, Ventricular Tachycardia, Cardiomyopathy, Dilated","enrollment":162},{"nctId":"NCT05253651","phase":"PHASE3","title":"A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2022-10-24","conditions":"Colorectal Neoplasms","enrollment":400},{"nctId":"NCT04532346","phase":"EARLY_PHASE1","title":"Hydroxychloroquine in Children's Interstitial Lung Diseases With Genetic Causes","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2024-09-01","conditions":"Interstitial Lung Disease, Surfactant Dysfunction","enrollment":60},{"nctId":"NCT05935761","phase":"PHASE2","title":"Investigating Novel Interventions for Low Back Pain in US Military Veterans: A Randomized Controlled Adaptive Phase II Trial","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-06-01","conditions":"Chronic Low Back Pain","enrollment":108},{"nctId":"NCT04389632","phase":"PHASE1","title":"A Study of Sigvotatug Vedotin in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2020-06-08","conditions":"Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms","enrollment":1006},{"nctId":"NCT04926285","phase":"PHASE1","title":"Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2022-06-21","conditions":"Relapsed or Refractory Hematologic Malignancies","enrollment":6},{"nctId":"NCT07387354","phase":"PHASE1, PHASE2","title":"Pacritinib With Aza for Upfront Myelodysplastic Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2026-05","conditions":"Myelodysplastic Syndromes, MDS, Myelodysplastic Syndrome, Unclassifiable","enrollment":25},{"nctId":"NCT07472868","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"J. W. A. Burger","startDate":"2026-03-03","conditions":"Locally Advanced Rectal Carcinoma","enrollment":394},{"nctId":"NCT03485209","phase":"PHASE2","title":"Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2018-06-25","conditions":"Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer","enrollment":352},{"nctId":"NCT05562830","phase":"PHASE1, PHASE2","title":"A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-11-16","conditions":"Urothelial Carcinoma","enrollment":48},{"nctId":"NCT07471347","phase":"NA","title":"Exploring The Effect Of Cannabidiol On Cannabis Tolerance Using A Novel Vaporiser Device In Heavy Users (Stage 1)","status":"NOT_YET_RECRUITING","sponsor":"King's College London","startDate":"2026-03","conditions":"Cannabis Intoxication","enrollment":10},{"nctId":"NCT06681220","phase":"PHASE1, PHASE2","title":"Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-02-23","conditions":"Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer","enrollment":166},{"nctId":"NCT07417189","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )","status":"RECRUITING","sponsor":"Abbisko Therapeutics Co, Ltd","startDate":"2026-03-02","conditions":"Solid Tumors, Adult","enrollment":401},{"nctId":"NCT07052890","phase":"NA","title":"Curcumin, Vitamin D and Green Tea in IBS-D","status":"COMPLETED","sponsor":"Dr Anthony Hobson","startDate":"2024-09-19","conditions":"Irritable Bowel Syndrome (IBS), Irritable Bowel Syndrome With Diarrhea (IBS-D)","enrollment":78},{"nctId":"NCT07457528","phase":"PHASE2","title":"Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-03-12","conditions":"Resectable Esophageal Squamous Cell Carcinoma","enrollment":46},{"nctId":"NCT03875820","phase":"PHASE1","title":"Phase I Trial of Defactinib and VS-6766.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2017-12-12","conditions":"NSCLC, Low Grade Serous Ovarian Cancer, Endometrioid Carcinoma","enrollment":87},{"nctId":"NCT06192979","phase":"NA","title":"Optimize First-line Treatment for AL Amyloidosis With t (11; 14)","status":"RECRUITING","sponsor":"Jin Lu, MD","startDate":"2024-01-05","conditions":"Amyloidosis; Systemic, AL Amyloidosis","enrollment":41},{"nctId":"NCT07454772","phase":"PHASE1, PHASE2","title":"Antibiotics vs Corticosteroids in Treatment of Granulomatous Lobular Mastitis","status":"NOT_YET_RECRUITING","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2026-03-15","conditions":"Granulomatous Mastitis","enrollment":72},{"nctId":"NCT03836248","phase":"NA","title":"Study of the Contribution of Osteopathic Treatment to Classic Medical Management in Patients With Chronic Low Back Pain","status":"RECRUITING","sponsor":"Clinique Pasteur","startDate":"2019-10-02","conditions":"Chronic Low Back Pain","enrollment":199},{"nctId":"NCT05268003","phase":"PHASE2","title":"A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-06-07","conditions":"Acute Lymphoblastic Leukemia, Leukemia","enrollment":26},{"nctId":"NCT05603702","phase":"PHASE1","title":"STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis","status":"RECRUITING","sponsor":"Indiana University","startDate":"2023-03-17","conditions":"Chronic Pain, Chronic Pain Syndrome, Chronic Pancreatitis","enrollment":24},{"nctId":"NCT04802590","phase":"PHASE2","title":"Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2022-01-24","conditions":"Mantle Cell Lymphoma","enrollment":194},{"nctId":"NCT05065801","phase":"PHASE2","title":"Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients","status":"RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2022-01-11","conditions":"Metastatic Pancreatic Cancer","enrollment":162},{"nctId":"NCT06671002","phase":"PHASE4","title":"Comparing Analgesic Regimen Effectiveness and Safety for Surgery for Kids Trial","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2025-01-10","conditions":"Surgery, Pain, Post Operative","enrollment":900},{"nctId":"NCT05846867","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2023-05-08","conditions":"Colorectal Cancer","enrollment":170},{"nctId":"NCT07044544","phase":"PHASE1","title":"Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-07-17","conditions":"Myeloid Malignancy, Hematologic Malignancy, Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT07309614","phase":"PHASE3","title":"A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma","status":"RECRUITING","sponsor":"Université de Sherbrooke","startDate":"2026-01-29","conditions":"Asthma Control","enrollment":150},{"nctId":"NCT05174169","phase":"PHASE2, PHASE3","title":"Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2022-03-10","conditions":"Stage III Colon Cancer","enrollment":1912},{"nctId":"NCT07050173","phase":"PHASE1","title":"Monitoring Patients With Repetitive Head Impact With Gamma-glutamylcysteine Supplementation","status":"RECRUITING","sponsor":"Pravat Mandal","startDate":"2026-03-20","conditions":"Repetitive Head Impacts","enrollment":30},{"nctId":"NCT05977907","phase":"PHASE2","title":"Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-12-14","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT06982521","phase":"PHASE3","title":"Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Relay Therapeutics, Inc.","startDate":"2025-08-26","conditions":"PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor","enrollment":540},{"nctId":"NCT07444619","phase":"PHASE1","title":"A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-08-31","conditions":"Soft Tissue Sarcomas","enrollment":18},{"nctId":"NCT07446270","phase":"PHASE2","title":"Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2026-03-03","conditions":"Treatment for Advanced Colorectal Cancer, Treatment for Advanced Pancreatic Cancer","enrollment":90},{"nctId":"NCT05949190","phase":"NA","title":"Improving Cognition and Gestational Duration With Targeted Nutrition","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-08-18","conditions":"Malnutrition in Pregnancy, Preterm Birth, Child Development","enrollment":1660},{"nctId":"NCT04903314","phase":"PHASE1","title":"Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures","status":"COMPLETED","sponsor":"SK Life Science, Inc.","startDate":"2021-05-27","conditions":"Partial Epilepsy","enrollment":26},{"nctId":"NCT07441369","phase":"PHASE2","title":"Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Fudan University","startDate":"2026-03-01","conditions":"Liver Metastases From Colorectal Cancer (mCRC)","enrollment":16},{"nctId":"NCT06452602","phase":"PHASE2","title":"Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-06-19","conditions":"Esophageal Cancer","enrollment":60},{"nctId":"NCT06078696","phase":"PHASE1, PHASE2","title":"Siplizumab for Sickle Cell Disease Transplant","status":"TERMINATED","sponsor":"Columbia University","startDate":"2023-09-28","conditions":"Anemia, Sickle Cell","enrollment":1},{"nctId":"NCT06230861","phase":"NA","title":"Effects of Quercetin on Cardiometabolic Outcomes","status":"RECRUITING","sponsor":"University of Central Lancashire","startDate":"2024-03-01","conditions":"Cardiometabolic Syndrome","enrollment":40},{"nctId":"NCT05650723","phase":"PHASE2","title":"Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2023-05-08","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":50},{"nctId":"NCT06943794","phase":"NA","title":"Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-03-30","conditions":"Gastric (Stomach) Cancer","enrollment":4824},{"nctId":"NCT06052813","phase":"PHASE1, PHASE2","title":"A Study of BN104 in the Treatment of Acute Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut de Recherches Internationales Servier (I.R.I.S.)","startDate":"2023-10-19","conditions":"ALL, Adult, AML, Adult, Acute Leukaemia","enrollment":66},{"nctId":"NCT07429760","phase":"NA","title":"Mechanical Bowel Preparation With or Without Oral Antibiotics in Left Sided Colorectal Cancer Surgery","status":"ENROLLING_BY_INVITATION","sponsor":"Shaukat Khanum Memorial Cancer Hospital & Research Centre","startDate":"2025-08-01","conditions":"Colorectal Cancer","enrollment":60},{"nctId":"NCT01356290","phase":"PHASE2","title":"Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2014-04","conditions":"Medulloblastoma Recurrent, Ependymoma Recurrent, ATRT Recurrent","enrollment":232},{"nctId":"NCT05513560","phase":"PHASE2, PHASE3","title":"RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2023-05-31","conditions":"Long COVID, Post COVID Condition, Post Acute Sequelae of COVID-19","enrollment":460},{"nctId":"NCT03395210","phase":"PHASE2","title":"A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)","status":"COMPLETED","sponsor":"Principia Biopharma, a Sanofi Company","startDate":"2018-03-22","conditions":"Immune Thrombocytopenia","enrollment":86},{"nctId":"NCT06307184","phase":"","title":"Assessing the Convenience of Natural Proliferative Phase Frozen Embryo Transfer","status":"RECRUITING","sponsor":"Instituto Valenciano de Infertilidade de Lisboa","startDate":"2024-02-23","conditions":"Frozen Embryo Transfer","enrollment":530},{"nctId":"NCT04562766","phase":"PHASE3","title":"Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Principia Biopharma, a Sanofi Company","startDate":"2020-12-14","conditions":"Immune Thrombocytopenia","enrollment":232},{"nctId":"NCT06782542","phase":"PHASE2","title":"Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy","status":"RECRUITING","sponsor":"Justin Watts, MD","startDate":"2026-05-01","conditions":"Acute Myeloid Leukemia, IDH1 Mutation","enrollment":16},{"nctId":"NCT06855212","phase":"PHASE2","title":"Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2025-02-26","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":21},{"nctId":"NCT07409844","phase":"PHASE2","title":"Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer","status":"NOT_YET_RECRUITING","sponsor":"Ismail Gögenur","startDate":"2026-03-01","conditions":"DMMR Colorectal Cancer, Colon Cancer Stage I, Colon Cancer Stage II/III","enrollment":152},{"nctId":"NCT04906902","phase":"PHASE1, PHASE2","title":"Acalabrutinib in CNSL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-08-23","conditions":"Central Nervous System Lymphoma, Refractory Central Nervous System Lymphoma, Recurrent Central Nervous System Lymphoma","enrollment":49},{"nctId":"NCT07382726","phase":"PHASE1","title":"Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-07-01","conditions":"Non-small Cell Lung Cancer","enrollment":18},{"nctId":"NCT07419464","phase":"PHASE2","title":"5-Fluorouracil Response and Optimization STudy (The FROST Trial)","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-05-31","conditions":"Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma, Recurrent Squamous Cell Carcinoma of the Head and Neck","enrollment":46},{"nctId":"NCT05041907","phase":"PHASE2","title":"Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2021-09-30","conditions":"COVID-19","enrollment":3800},{"nctId":"NCT07418879","phase":"NA","title":"A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-02-05","conditions":"Non-small Cell Lung Cancer, RET Fusion, Pralsetinib","enrollment":25},{"nctId":"NCT05496036","phase":"PHASE2","title":"Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2023-02-13","conditions":"Merkel Cell Carcinoma","enrollment":15},{"nctId":"NCT07412080","phase":"PHASE1","title":"EDP167 in Healthy Volunteers and Subjects With Mild Dyslipidemia","status":"COMPLETED","sponsor":"Eddingpharm (Zhuhai) Co., Ltd.","startDate":"2025-07-01","conditions":"Healthy Adult Male and Female Volunteers, Mild Dyslipidemia","enrollment":40},{"nctId":"NCT06435026","phase":"PHASE2","title":"Optimizing PrEP Regimens for Pregnant Women in Sub-Saharan Africa (O-PrEP Study) - Stage 1","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2024-06-18","conditions":"HIV, Prevention, Pregnancy","enrollment":54},{"nctId":"NCT04432597","phase":"PHASE1, PHASE2","title":"HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-08-11","conditions":"HPV Positive Cancer, Vulvar, Vaginal, Penile, Rectal Cancer, Anal Cancer","enrollment":39},{"nctId":"NCT04903119","phase":"PHASE1","title":"Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma","status":"RECRUITING","sponsor":"Rina Plattner","startDate":"2022-06-01","conditions":"Metastatic Melanoma, BRAF Gene Mutation","enrollment":30},{"nctId":"NCT07349758","phase":"PHASE1","title":"Evaluation of Single Dosing With Two F/TAF Tablets Among Healthy Volunteers","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-01-06","conditions":"Healthy Volunteer, HIV Prevention","enrollment":24},{"nctId":"NCT05995535","phase":"PHASE2","title":"Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2024-01-01","conditions":"Opiate Withdrawal Syndrome, Opioid Use","enrollment":150},{"nctId":"NCT03504397","phase":"PHASE3","title":"A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-06-21","conditions":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer","enrollment":565},{"nctId":"NCT05053659","phase":"PHASE1","title":"Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Paolo Caimi, MD","startDate":"2022-06-20","conditions":"Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma","enrollment":23}],"_emaApprovals":[],"_faersSignals":[],"administration":{"route":"Oral"},"_approvalHistory":[],"publicationCount":2342,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"400mg","genericName":"400mg","companyName":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","companyId":"cspc-zhongqi-pharmaceutical-technology-co-ltd","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T04:29:13.122917+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}